Reactions Weekly

, Volume 1636, Issue 1, pp 183–183 | Cite as

Ipilimumab/nivolumab

Various toxicities: case report
Case report
  • 29 Downloads

Reference

  1. Lowe JR, et al. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. Journal for ImmunoTherapy of Cancer : 89. Date, No. 89, 20 Dec 2016 - USAGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations